PD-5 IDH1 in intrahepatic cholangiocarcinoma: A comparative genomic analysis and clinical impact

IDH1-mutated cholangiocarcinomas (CCAs) are an interesting group of neoplasia with particular behavior and therapeutic implications. The aim the present work is to highlight differences characterizing IDH1m IDH1wt CCAs in terms genomic landscape. 284 patients iCCA treated for resectable, locally advanced or metastatic disease were selected studied FOUNDATION Cdx technology. A comparative analysis survival analyses most relevant altered genes performed between patients. Overall, 125 122 IDH1wt. showed higher mutation rates compared CDKN2B lower several including TP53, FGFR2, BRCA2, ATM, MAP3K1, NOTCH2, ZNF703, CCND1, NBN, NF1, MAP3KI3, RAD21. At analysis, no statistically outcomes, but a trend favor was observed. Differences prognostic values common reported. In surgical setting, presence CDKN2A mutations negatively impact DFS, whereas CDKN2A, CDKN2B, PBRM1 OS. group, KRAS/NRAS TP53 PFS, PIK3CA OS; only MTAP We highlighted molecular distinct implications